Disease · MONDO_0001402
vaginal cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. vaginal cancer. Diseases, record MONDO_0001402. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001402
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
cancer of vagina, malignant neoplasm of the vagina, malignant neoplasm of vagina, malignant tumor of the vagina, malignant tumor of vagina, malignant tumour of the vagina, malignant tumour of vagina, malignant vagina neoplasm, malignant vagina tumor, malignant vagina tumour, malignant vaginal neoplasm, malignant vaginal tumor, malignant vaginal tumour, vagina cancer
- Open Targets
Drugs28
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| TRIAPINE | CHEMBL231616 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| ALDESLEUKIN | CHEMBL1201438 | Protein | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| BINTRAFUSP ALFA | CHEMBL4298024 | Protein | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| FLUDARABINE | CHEMBL1568 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BECOTATUG VEDOTIN | CHEMBL6068210 | Antibody drug conjugate | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BORTEZOMIB | CHEMBL325041 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DISITAMAB VEDOTIN | CHEMBL5095273 | Antibody drug conjugate | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES | CHEMBL6068359 | Vaccine component | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 28
See all 28 drugsTargets126
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CD274 | Programmed cell death 1 ligand 1 | 3 | Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| CTLA4 | Cytotoxic T-lymphocyte protein 4 | 2 | Cytotoxic T-lymphocyte protein 4 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/1493 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 2 | Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| ADRM1 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/11047 | Drugs and targets |
| CD38 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | 1 | Lymphocyte differentiation antigen CD38 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/952 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4697 | Drugs and targets |
| COXFA4L2 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/56901 | Drugs and targets |
| CRBN | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 1 | https://conductscience.org/library/genes/51185 | Drugs and targets |
| CUL4A | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 1 | https://conductscience.org/library/genes/8451 | Drugs and targets |
| DDB1 | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 1 | https://conductscience.org/library/genes/1642 | Drugs and targets |
1 to 10 of 126
See all 126 targetsTrials24
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02488759 | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors | Phase 1/2 | 578 | 2022-04-12 | Various Advanced Cancer | DARATUMUMAB, IPILIMUMAB, NIVOLUMAB, RELATLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02466971 | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers | Phase 3 | 450 | 2024-01-05 | Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IV Vaginal Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVA Vaginal Cancer AJCC v6 and v7, Unresectable Vaginal Carcinoma, Vaginal Adenocarcinoma, Vaginal Adenosquamous Carcinoma, Vaginal Carcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified | CISPLATIN, TRIAPINE | Its record names the disease | ClinicalTrials.gov |
| NCT02858310 | E7 TCR T Cells for Human Papillomavirus-Associated Cancers | Phase 1/2 | 224 | 2026-03-09 | Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT03427411 | M7824 in Subjects With HPV Associated Malignancies | Phase 2 | 57 | 2022-02-28 | Human Papilloma Virus, Cervical Cancer, Oropharyngeal Cancer, Anal Cancer, Vaginal or Penile Cancer | BINTRAFUSP ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT04287868 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | Phase 1/2 | 51 | 2023-11-18 | Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer, Vulvar, Vaginal, Penile, Rectal Cancer | BINTRAFUSP ALFA, IMMUNOCYTOKINE NHS-IL12, PEXIPEPIMUT-S | Its record names the disease | ClinicalTrials.gov |
| NCT01585428 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers | Phase 2 | 29 | 2017-03-23 | Cervical Cancer, Oropharyngeal Cancer, Vaginal Cancer, Anal Cancer, Penile Cancer | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT00941070 | Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer | Phase 2 | 26 | 2013-05-13 | Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Stage IB Cervical Cancer, Stage II Vaginal Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Vaginal Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Therapy-related Toxicity | CISPLATIN, TRIAPINE | Its record names the disease | ClinicalTrials.gov |
| NCT02595879 | Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer | Phase 1 | 21 | 2024-10-16 | Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma, Advanced Cervical Squamous Cell Carcinoma, Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVA Vaginal Cancer AJCC v6 and v7 | CISPLATIN, TRIAPINE | Its record names the disease | ClinicalTrials.gov |
| NCT02280811 | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | Phase 1/2 | 12 | 2017-08-02 | Vaginal Cancer, Cervical Cancer, Anal Cancer, Penile Cancer, Oropharyngeal Cancer | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT03345784 | Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers | Phase 1 | 10 | 2023-06-06 | Cervical Carcinoma, Endometrioid Adenocarcinoma, Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Stage I Uterine Corpus Cancer AJCC v7, Stage I Vaginal Cancer AJCC v6 and v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Cervical Cancer AJCC v6 and v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7, Stage III Uterine Corpus Cancer AJCC v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Vaginal Carcinoma | ADAVOSERTIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 24
See all 24 trialsComparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm I (Cisplatin, IMRT or RT, Brachytherapy) vs Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine): deaths from any cause | 35 of 224 | 34 of 224 | 448 | NCT02466971 | Trial comparisons |
| Arm I (Cisplatin, IMRT or RT, Brachytherapy) vs Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine): serious adverse events | 45 of 208 | 45 of 202 | 410 | NCT02466971 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | 30 of 30 | 26 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: Number of Participants With Serious Grade ≥3 Adverse Events Considered Related to Study Treatment of M7824 | 6 of 30 | 4 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: deaths from any cause | 18 of 30 | 22 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: serious adverse events | 19 of 30 | 21 of 26 | 56 | NCT03427411 | Trial comparisons |
Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 47 of 47 | 3 of 3 | 50 | NCT04287868 | Trial comparisons |
| Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: deaths from any cause | 28 of 47 | 0 of 3 | 50 | NCT04287868 | Trial comparisons |
| Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: serious adverse events | 18 of 47 | 1 of 3 | 50 | NCT04287868 | Trial comparisons |
| Cervical vs NonCervical: Number of Patients With Serious and Non-serious Adverse Events | 18 of 18 | 11 of 11 | 29 | NCT01585428 | Trial comparisons |
1 to 10 of 17
See all 17 comparisons in its trialsPapers from its trials21
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001402
GET https://conductscience.org/api/diseases/v1/MONDO_0001402/drugs?page=2